Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


The Latest In Amyotrophic Lateral Sclerosis Drug R&D

There is significant R&D activity focused on the rapid development of effective treatments for amyotrophic lateral sclerosis (ALS). Supported by specialist consortia such as the Northeast ALS Consortium (NEALS) in the US and the Treatment Research Initiative to Cure ALS (TRICALS) in Europe, industry pipeline assets are being evaluated across a range of clinical trials, including platform trials.

Download our whitepaper to find out more about:

  • Disease overview & epidemiology of ALS
  • The ALS drug pipeline
  • Mid stage programs
  • Expected near term approvals
  • The emergence of genetic therapies

alt text

Complete the form to download your free Amyotrophic Lateral Sclerosis Drug R&D Whitepaper!

By ticking this box, you agree to receive emails such as relevant news, updates and offers from Informa Business Intelligence, and carefully selected similar products from our portfolio
By ticking this box, you agree to receive emails such as promotional offers from other members of the Informa group and selected 3rd party companies